Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARLDIFER
2024-512018-16-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Recurrence-free survival rate at 12 months. Started Aug 2024; status: completed.
02
Drugs
pemigatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-512018-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512018-16-00.